Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $280.7 million.

  • Enanta Pharmaceuticals' Liabilities and Shareholders Equity fell 2546.65% to $280.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 2251.17%. This contributed to the annual value of $280.7 million for FY2025, which is 2546.65% down from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Liabilities and Shareholders Equity stood at $280.7 million, which was down 2546.65% from $301.0 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Liabilities and Shareholders Equity peaked at $495.2 million during Q2 2023, and registered a low of $280.7 million during Q3 2025.
  • In the last 5 years, Enanta Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $398.8 million in 2024 and averaged $393.0 million.
  • In the last 5 years, Enanta Pharmaceuticals' Liabilities and Shareholders Equity soared by 2854.39% in 2023 and then crashed by 2546.65% in 2025.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Liabilities and Shareholders Equity stood at $440.6 million in 2021, then fell by 21.12% to $347.5 million in 2022, then rose by 23.3% to $428.5 million in 2023, then decreased by 18.64% to $348.6 million in 2024, then decreased by 19.48% to $280.7 million in 2025.
  • Its last three reported values are $280.7 million in Q3 2025, $301.0 million for Q2 2025, and $323.0 million during Q1 2025.